Scarica l'app Stockscreener
18.09
0.95%
0.17
Dopo l'orario di chiusura:
17.80
-0.29
-1.60%
Precedente Chiudi:
$17.92
Aprire:
$18.06
Volume 24 ore:
1.19M
Relative Volume:
0.63
Capitalizzazione di mercato:
$5.78B
Reddito:
$3.05B
Utile/perdita netta:
$181.32M
Rapporto P/E:
48.50
EPS:
0.373
Flusso di cassa netto:
$186.11M
1 W Prestazione:
+3.37%
1M Prestazione:
+4.99%
6M Prestazione:
+30.80%
1 anno Prestazione:
+124.44%
Intervallo 1D:
$17.89
$18.19
Intervallo di 1 settimana:
$17.45
$18.20
Portata 52W:
$7.665
$18.39
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
Nome
Amneal Pharmaceuticals Inc
Settore
Telefono
908-947-3120
Indirizzo
400 Crossing Boulevard, 3rd Floor, Bridgewater
Compare AMRX vs TAK, HLN, TEVA, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
18.09 | 5.72B | 3.05B | 181.32M | 186.11M | 0.373 |
TAK
Takeda Pharmaceutical Co Adr
|
17.44 | 55.06B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.94 | 43.07B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.08 | 35.88B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
76.92 | 31.59B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
527.94 | 26.32B | 3.17B | 1.29B | 1.01B | 27.09 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-17 | Iniziato | UBS | Buy |
| 2025-12-09 | Iniziato | Barclays | Overweight |
| 2025-06-06 | Iniziato | Goldman | Buy |
| 2025-02-24 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-09-06 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2021-03-08 | Aggiornamento | Goldman | Sell → Buy |
| 2020-12-14 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2020-12-14 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-07-27 | Iniziato | Goldman | Sell |
| 2020-05-12 | Aggiornamento | Guggenheim | Sell → Neutral |
| 2019-12-12 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2019-11-12 | Downgrade | JP Morgan | Neutral → Underweight |
| 2019-11-07 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2019-07-22 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-07-11 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-07-08 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2019-06-11 | Iniziato | Barclays | Equal Weight |
| 2019-05-21 | Aggiornamento | Raymond James | Mkt Perform → Strong Buy |
| 2019-03-20 | Iniziato | SunTrust | Buy |
| 2019-03-08 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2018-12-14 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2018-10-16 | Downgrade | SunTrust | Buy → Hold |
| 2018-08-13 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-07-23 | Iniziato | Morgan Stanley | Overweight |
| 2018-06-22 | Iniziato | B. Riley FBR, Inc. | Buy |
Mostra tutto
Amneal Pharmaceuticals Inc Borsa (AMRX) Ultime notizie
AMRX|Amneal Pharmaceuticals Inc|Price:17.920|Chg%:-0.050 - TradingKey
How Investors May Respond To Amneal Pharmaceuticals (AMRX) Expanding Its Iohexol Generic Portfolio Across OMNIPAQUE Formats - Sahm
ETFs Investing in Amneal Pharmaceuticals, Inc. Class A Stocks - TradingView
Amneal Pharmaceuticals Inc (AMRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Kaskela Law LLC Announces Investigation of Amneal Pharmaceuticals, Inc. (AMRX) and Encourages AMRX Shareholders to Contact the Firm - Business Wire
Goldman Sachs Initiates Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Announces Target Price $19 - Moomoo
AMRX: Amneal Pharmaceuticals IncOrdinary SharesClass A Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Amneal: Kashiv Deal Fuels Biosimilar Growth, But Stock Already Prices In Optimism (AMRX) - Seeking Alpha
Here's why Amneal Pharmaceuticals (AMRX) is a strong growth stock - MSN
Amneal Pharmaceuticals (AMRX) Proxy filing Summary - Quartr
How First-Generic OMNIPAQUE Rivals At Amneal Pharmaceuticals (AMRX) Have Changed Its Investment Story - Sahm
Amneal receives FDA approval for additional iohexol strengths By Investing.com - Investing.com South Africa
Amneal receives FDA approval for additional iohexol strengths - Investing.com
Amneal Expands Iohexol Injection Portfolio with U.S. FDA Approval of Additional Strengths and Presentations - The Manila Times
Amneal Pharmaceuticals Receives FDA Approval for Additional Iohexol Injection Strengths and Vial Presentations - Quiver Quantitative
Amneal's FDA-approved contrast options give hospitals more vial choices - Stock Titan
Amneal gains FDA approval for four iohexol products - grafa.com
Amneal Pharmaceuticals stock hits 52-week high at 17.86 USD By Investing.com - Investing.com South Africa
Amneal Pharmaceuticals stock hits 52-week high at 17.86 USD - Investing.com
Is Amneal Pharmaceuticals (AMRX) Fairly Valued After Its Sharp Rerating? - Sahm
3 Reasons AMRX is Risky and 1 Stock to Buy Instead - Yahoo Finance
Amneal Pharmaceuticals (AMRX) Barclays 28th Annual Global Healthcare Conference summary - Quartr
Amneal Pharmaceuticals stock holds steady as generic pipeline supports long term growth - Ad-hoc-news.de
Amneal schedules July 30 call for second-quarter 2026 results - Stock Titan
Amneal to Report Second Quarter 2026 Results on July 30, 2026 - The Manila Times
Amneals Planned Sterile Facility Creates Opportunity For Aseptic Filling Isolator And Automation Suppliers - Pharmaceutical Online
Enterprise value to revenue forward of Amneal Pharmaceuticals, Inc. – NASDAQ:AMRX - TradingView
Generic Pharmaceuticals Stocks Q4 In Review: Amneal (NASDAQ:AMRX) Vs Peers - Yahoo Finance
Amneal Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Kiely John - Moomoo
Amneal Sues Alembic to Block Copies of Crexont Parkinson’s Drug - Bloomberg Law News
Amneal Pharmaceuticals updates investors on its generics and specialty pipeline. The company focuses - ad-hoc-news.de
$2M from Amneal targets Parkinson's drug costs for patients - Stock Titan
Amneal Pharmaceuticals (AMRX) Gets EU Backing For Hopledo, Is It Fully Priced? - Sahm
Price to sales forward of Amneal Pharmaceuticals, Inc. – NASDAQ:AMRX - TradingView
Amneal Pharmaceuticals : New U.S. Sterile Manufacturing Facility Selected for FDA PreCheck Pilot Program - marketscreener.com
Price to book forward of Amneal Pharmaceuticals, Inc. – NASDAQ:AMRX - TradingView
Price to earnings forward of Amneal Pharmaceuticals, Inc. – NASDAQ:AMRX - TradingView
Eli Lilly, Regeneron Join FDA Pilot Designed To Accelerate US Manufacturing Readiness - Sahm
Lilly, Regeneron selected for US program to review new manufacturing plants faster - Reuters
Amneal to Buy Kashiv for $375M Cash + 28.9M Shares (NASDAQ: AMRX) - Stock Titan
EMA Recommends Approval of Hopledo for Parkinson's Disease - Intellectia AI
Zambon and Amneal Receive Positive CHMP Opinion for Hopledo in Parkinson’s Disease in Europe - Quiver Quantitative
Zambon and Amneal Announce Positive CHMP Opinion for - GlobeNewswire
Does Amneal (AMRX) Joining Three Russell 2000 Defensive Indexes Recast Its Risk Profile? - simplywall.st
Amneal Pharmaceuticals, Inc.(NasdaqGS:AMRX) added to Russell 2000 Value-Defensive Index - marketscreener.com
Amneal Pharmaceuticals, Inc.(NasdaqGS:AMRX) added to Russell 2000 Growth-Defensive Index - marketscreener.com
Amneal Pharmaceuticals, Inc.(NasdaqGS: AMRX) added to Russell 2000 Defensive Index - marketscreener.com
Form DEF 14A Amneal Pharmaceuticals Inc Class A For: 26 June - Investing.com UK
2DT Forecast — Price Target — Prediction for 2027 - TradingView
Amneal Pharmaceuticals, Inc. Class A Actuals & Estimates (NASDAQ:AMRX) - TradingView
AMRX Forecast — Price Target — Prediction for 2027 - TradingView
Amneal Pharmaceuticals Inc Azioni (AMRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.30%
2.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):